PRM110 Planning and Executing Qualitative Research With Adolescents in an Orphan Disease  by Cole, J.C. et al.
and SG outcomes from members of the general public who were asked to evaluate
hypothetical health states. Two researchers, with a third acting as adjudicator,
independently undertook the review of the literature, the inclusion/exclusion pro-
cess and data extraction. Statistical analyses were performed on study arms (stud-
ies) for differences and/or correlation between utility scores derived from TTO and
SG. RESULTS: Of the 170 publications yielded by the initial literature search, 19
pertinent articles were included in the present analysis, covering 24 disease cate-
gories, 77 studies and 17,515 subjects. The overall weighted mean health utility
scores were 0.82 with TTO and 0.83 with SG. Studies reporting a greater than 10%
absolute difference between the two measurement tools represented 13% (k10),
while 22% reported greater than 10% relative difference (k17), 51% reported over-
all higher utility scores with SG (k39) and 13% reported equal scores (k10). The
most common disease category, discussed in 8 studies covering 2,490 participants,
was ocular disease. Spearman’s rank test yielded significant positive correlation (r
 0.924). CONCLUSIONS: The majority of studies displayed little difference in
scores between the TTO and SG methods collected from the general public. A high
positive correlation was observed between utility scores reported by the two meth-
ods.
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OBJECTIVES: As the patient perspective becomes increasingly critical in this era of
patient-centric care and patient cost-sharing, a better understanding of research
methodologies and their impact on validity of responses is required to assess the
growing body of patient research. Increasingly, researchers are able to leverage
technology in order to access patient panels; however, questions remain as to their
robustness and representativeness. Here, we review the underlying survey re-
sponse differences obtained from both nonprobability and probability-based pa-
tient samples accessed via online survey panels and the potential impact to pa-
tient-centered research. METHODS: A review was conducted of a mixed-method
patient survey examining self-identified smokers and motivation to quit, which
utilized both probability and nonprobability samples. Survey results were com-
pared from 1,427 probability and 5,425 nonprobability patient samples. The prob-
ability sample was obtained from a statistically valid online panel, representative
of the US population. Survey responses between groups were compared using
Student’s t-test and Chi-square tests. RESULTS: The probability sample reported
smoking more cigarettes per day (p0.001) and were more likely to report smoking
every day (p0.001). Additionally, patients in the nonprobability sample were more
likely to report that they planned to quit smoking in the next 30 days (p0.001) and
that they had made an attempt to quit smoking in the past 6 months (p0.001).
CONCLUSIONS: Survey results for patient reported outcomes studies obtained
through nonprobability sampling varied significantly from those obtained through
probability sampling; and response variation is unpredictable. Calibrating non-
probability samples with probability samples using specific screening questions
may minimize bias in the resulting estimates in the larger combined sample. In
order for patient-centered outcomes research to play a meaningful role in health
care policy and decision making, rigorous probability sampling methodologies
must be applied in order to allow interpretation of results with high confidence.
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OBJECTIVES: This study assessed the measurement properties of the Functional
Assessment of Cancer Therapy – Anaemia (FACT-An) for use in patients with anae-
mia associated with chronic kidney disease (CKD). METHODS: FACT-An data were
collected in an open label dose titration, randomised phase 2b clinical trial (study
FGCL-4592-041) with non-dialysis CKD patients with anaemic stages 3 and 4.
FACT-An was completed at baseline, and treatment Weeks 9 and 17. RESULTS:
Data from 145 patients were analyzed. Average age was 64.4 yrs (SD11.3), 63%
were female. Average hemoglobin (Hb) level was 9.7 g/dL (SD0.7), 11.4 (SD1.2),
and 11.7 (SD1.1) at baseline, Weeks 9 and 17, respectively. Internal consistency
and test-retest reliability were 0.70 for all subscales, except the Emotional Well-
being subscale (EWB). Convergent validity was shown by correlations between
FACT-An Total score, Anaemia subscale, and Fatigue subscale with SF-36v2 Phys-
ical Functioning (0.57-0.61) and Vitality (0.73-0.76). Correlations were low between
FACT-An Total score, Anaemia subscale, and Fatigue subscale and Hb level at
baseline (0.14-0.15), but increased at treatment Weeks 9 (0.16-0.20) and 17 (0.23-
0.26). A responder analysis showed that FACT-An Anaemia and Fatigue subscales
were responsive in detecting small but significant changes in Hb level at week 9.
The FACT-An Total score, Anaemia subscale, and Fatigue subscale, were able to
detect SF-36v2 Vitality score increase of 5 points from baseline to Week 17. Based
on distributional and anchor-based methods, the minimally important difference
was estimated as score change of 8-10 for FACT-An Total score, 4-7 for Anaemia
subscale, and 3-5 for Fatigue subscale. CONCLUSIONS: This study shows the
FACT-An Total score, Anaemia subscale, and Fatigue subscale to be a reliable, valid,
and responsive instrument for CKD patients with anaemia. Results on the ability to
detect Hb changes were limited due to the narrow range of Hb values available in
this study.
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OBJECTIVES: To test the face and content validity of the US-English version of draft
patient satisfaction questionnaires for subcutaneous (SC) (referred to as the ‘RASQ-
SC’) and intravenous (IV) (referred to as the ‘RASQ-IV’) administrations of treat-
ment for Non-Hodgkin’s Lymphoma (NHL).METHODS:Qualitative interviews were
conducted with 10 US-English speaking adults from 2 US cities who had received an
IV administered NHL treatment in the past 4 weeks. The interviews began with a
concept elicitation (CE) section which focused on eliciting information relating to
the patients’ IV treatment experiences and perceptions of satisfaction and impacts
of a SC administration. Patients were then shown a short video showing the SC
administration process. The draft satisfaction questionnaires were then cogni-
tively debriefed (CD) using a “think-aloud” exercise to explore the content validity
of the RASQ-SC and the RASQ-IV. Interview transcripts were thematically analysed
using Atlas.ti software employing a grounded theory approach. RESULTS: Patients
were aged 43-77 years and 70% were female. Seventy percent of patients were
diagnosed with diffuse large B-cell lymphoma and 30% with indolent B-cell, stages
ranging from 1-4. Qualitative analysis demonstrated that the RASQ-IV and
RASQ-SC have excellent coverage of the treatment satisfaction and impact con-
cepts reported by patients in the CE section and during the debriefing of the RASQ-
IV. Patients’ demonstrated a good understanding of all item wording, instructions,
response scales and the recall period in the RASQ-SC. A small number of minor
revisions were made to further improve patient understanding and aid consistent
interpretation. CONCLUSIONS: The findings indicate that overall the RASQ-SC and
RASQ-IV had strong face and content validity and, following some minor revisions,
will measure the key differentiators that are important and relevant for the differ-
ent NHL treatment administration options. The instruments are appropriate for
inclusion in trials as secondary or exploratory endpoints.
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OBJECTIVES: The FDA’s Guidance for Industry, on Patient-Reported Outcome (PRO)
Measures: Use in Medical Product Development and to Support Labeling Claims
noted that validation of PRO in adults does not provide evidence for pediatrics[1].
PRO development and validation in pediatrics involves different processes, as out-
lined in a forthcoming ISPOR Good Research Practices report (GRPr)[2]. The research
objective was to consider recently implemented qualitative research strategies in
pediatrics aged 12-17 years with an orphan disease to inform the best practices for
PRO development in this population. METHODS: Consistent with the GRPr for PRO
research in pediatrics, focus groups (FGs) and individual interviews (IDIs) were
planned in Germany, Switzerland, Turkey, the UK and the United States (US). Dis-
cussions with local physicians preceded recruitment, which served as an opportu-
nity for them to relay parents’ concerns and reveal variances among adolescents
with an orphan disease. Informed consent and EC approval were obtained. A 2 x 2
(gender: female, male x age cohort: 12-14, 15-17) design of focus groups accommo-
dated social differences. RESULTS: Adolescent recruitment is complex, especially
in an orphan disease sample. Identifying eligible adolescents with an orphan dis-
ease who may remain asymptomatic until later in life was challenging, and parents
were not always willing to provide consent. Consequently, we conducted more IDIs
and fewer FGs than planned. Although US-based ethics review was a standard
process, European ECs had no formal process for concept elicitation and all issued
tacit or explicit waivers. CONCLUSIONS:Qualitative research for PRO development
in adolescents with an orphan disease requires a unique approach. We recom-
mend a 3-4 month lead time from protocol finalization to meeting commencement.
When designing protocol and recruitment strategies, researchers should ensure
adequate pediatric protections and seek EC approval. ECs should develop review
processes specifically for future PRO development research.
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Patient-reported outcome (PRO) assessment for pediatric populations is complex.
Potential variations in cognitive development and disease impact/treatment
across a wide age range present challenges for PRO assessment. Epidermolysis
bullosa (EB) is a rare, incurable genetic skin disorder primarily affecting children.
Common clinical manifestations are skin blistering and chronic wounds. Children
with EB and their families face numerous health-related quality of life (HRQOL)
issues. OBJECTIVES: To identify and evaluate HRQOL measures for use with chil-
dren (aged 3 years) with EB. METHODS: A structured PubMed search was con-
ducted using Medical Subject Heading search terms. Of the 143 abstracts identified,
40 were appropriate for further evaluation; 33 articles underwent full-text review.
Content validity and other psychometric properties of identified HRQOL measures
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